Northern Trust Corp Genprex, Inc. Transaction History

Northern Trust Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.76 - $1.78 $3,472 - $8,132	-4,569 Reduced 5.29%	81,861 $74,000
Q4 2022 Feb 13, 2023	BUY	$1.0 - $58.8 $11,029 - $648,505	11,029 Added 14.63%	86,430 $125,000
Q2 2022 Aug 12, 2022	SELL	$1.28 - $2.31 $4,211 - $7,599	-3,290 Reduced 4.18%	75,401 $105,000
Q3 2021 Nov 15, 2021	SELL	$2.59 - $3.36 $10,740 - $13,933	-4,147 Reduced 5.01%	78,691 $211,000
Q2 2021 Aug 13, 2021	SELL	$3.11 - $4.87 $784,659 - $1.23 Million	-252,302 Reduced 75.28%	82,838 $278,000
Q1 2021 May 12, 2021	SELL	$3.66 - $7.67 $24,983 - $52,355	-6,826 Reduced 2.0%	335,140 $1.45 Million
Q4 2020 Feb 11, 2021	BUY	$3.03 - $5.51 $7,508 - $13,653	2,478 Added 0.73%	341,966 $1.42 Million
Q3 2020 Nov 16, 2020	BUY	$2.9 - $4.29 $365 - $540	126 Added 0.04%	339,488 $1.14 Million
Q2 2020 Aug 14, 2020	BUY	$1.99 - $3.64 $633,564 - $1.16 Million	318,374 Added 1516.93%	339,362 $1.07 Million
Q1 2020 May 14, 2020	BUY	$0.28 - $6.23 $5,876 - $130,755	20,988 New	20,988 $51,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $39.9M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.